8-K: Travere Therapeutics Reports Q1 2026 Results, FILSPARI Drives Growth

Travere Therapeutics announced strong first quarter 2026 financial results, driven by significant year-over-year growth in FILSPARI net product sales and the recent FDA approval for FSGS.

Summary

• Travere Therapeutics reported first quarter 2026 financial results, with U.S. net product sales reaching $124.5 million, an 88% increase year-over-year, primarily due to FILSPARI sales.
• FILSPARI achieved record 993 new patient start forms for IgA Nephropathy (IgAN) in the U.S. during the quarter.
• The company received FDA approval for FILSPARI to treat Focal Segmental Glomerulosclerosis (FSGS) in April 2026, expanding its addressable patient population in the U.S. to over 100,000.
• Research and development expenses increased to $57.1 million, largely due to the restart of the Phase 3 HARMONY Study for pegtibatinase in classical Homocystinuria (HCU).
• Selling, general, and administrative expenses rose to $80.3 million, reflecting investments in the FILSPARI FSGS launch and IgAN commercial efforts.
• The net loss for the quarter was $37.1 million ($0.40 per share), an improvement from $41.2 million ($0.47 per share) in the prior year.
• On a non-GAAP adjusted basis, the company reported a net income of $4.1 million ($0.05 per share), a significant turnaround from a net loss of $16.9 million ($0.19 per share) in Q1 2025.
• As of March 31, 2026, the company had $264.7 million in cash, cash equivalents, and marketable securities.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive report, driven by strong sales growth, a significant regulatory approval, and improved profitability on a non-GAAP basis, despite increased R&D spending.

Positives

• U.S. net product sales grew 88% year-over-year to $124.5 million, driven by FILSPARI.
• FILSPARI achieved record 993 new patient start forms for IgAN in the U.S.
• FDA approval for FILSPARI in FSGS was secured in April 2026, expanding the addressable patient population to over 100,000.
• First FSGS patients were treated within one week of FILSPARI's approval.
• The first new patient was dosed in the restarted Phase 3 HARMONY Study of pegtibatinase.
• Non-GAAP adjusted net income was $4.1 million, a significant improvement from a net loss in the prior year.
• Cash, cash equivalents, and marketable securities stood at $264.7 million as of March 31, 2026.

Negatives

• GAAP net loss for the quarter was $37.1 million.
• Research and development expenses increased to $57.1 million.
• Selling, general, and administrative expenses increased to $80.3 million.
• Royalty expenses more than doubled year-over-year to $24.8 million.

Risks

• Risk of hepatotoxicity associated with FILSPARI, requiring enrollment in the FILSPARI REMS program.
• FILSPARI is contraindicated in pregnancy due to potential fetal harm, requiring effective contraception.
• Potential for hypotension, acute kidney injury, hyperkalemia, and fluid retention with FILSPARI use.
• Drug interactions with ARBs, ERAs, aliskiren, and CYP3A inhibitors/inducers require careful management.
• The restart of the Phase 3 HARMONY Study for pegtibatinase carries inherent risks associated with clinical trial execution and outcomes.
• The company faces risks associated with the commercial launch of FILSPARI in FSGS and ongoing commercial investments in IgAN.
• Future funding requirements may not be met due to macroeconomic conditions or other factors.
• Dependence on contractors for clinical drug supply and commercial manufacturing.

Future Outlook

The company anticipates a substantial and durable growth opportunity ahead with FILSPARI positioned to help over 100,000 patients across IgAN and FSGS, supporting a compelling long-term trajectory. Topline data from the Phase 3 HARMONY Study of pegtibatinase is expected in the second half of 2027. Enrollment in the SPARX Study is on track to complete in the second quarter of 2026.

Management Comments

• "This has been a transformative start to the year for Travere, highlighted by the landmark approval of FILSPARI in FSGS, record demand that reinforces FILSPARIs foundational position in IgAN, and the advancement of pegtibatinase with the first new patient dosed in the restarted Phase 3 HARMONY study."
• "With FILSPARI now positioned to help more than 100,000 patients across IgAN and FSGS, we see a substantial and durable growth opportunity ahead, supporting a compelling long-term trajectory for the Company."

Industry Context

StockSavvy.ai notes that Travere Therapeutics' Q1 2026 results demonstrate strong commercial execution for FILSPARI, particularly with the recent FSGS approval expanding its market potential. The company is navigating the complexities of rare disease drug development, with the restart of the pegtibatinase Phase 3 study indicating continued investment in its pipeline.

Stakeholder Impact

• Shareholders: Potential for increased value due to strong sales growth, regulatory approval, and improved financial performance.
• Patients: Expanded access to FILSPARI for both IgAN and FSGS patients, with potential for a new disease-modifying therapy for HCU.
• Healthcare Providers: New treatment options and data presentations at medical conferences.

Next Steps

• Present real-world data on combination treatment with FILSPARI and SGLT2 inhibitors in IgAN at the NKF Spring Clinical Meeting.
• Present additional Phase 3 DUPLEX data, including results from patients who switched from irbesartan to FILSPARI, at the NKF Spring Clinical Meeting.
• Complete enrollment in the SPARX Study evaluating FILSPARI in post-transplant patients in Q2 2026.
• Partner Chugai Pharmaceutical expects to submit a New Drug Application for sparsentan in Japan in 2026.
• Anticipate topline data from the Phase 3 HARMONY Study of pegtibatinase in 2H 2027.

Key Dates

Recommendation

While the Q1 2026 results show strong commercial momentum and a key regulatory approval, the company continues to operate at a GAAP net loss and has significant R&D investments planned. The outlook for pegtibatinase is still long-term, and the company faces ongoing risks associated with drug development and commercialization. A 'hold' recommendation reflects the positive developments balanced against the inherent risks and long-term nature of the pipeline.

Keywords

Travere Therapeutics, FILSPARI, sparsentan, IgAN, FSGS, pegtibatinase, HCU, Financial Results